A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
NCT01672736
Terminated
This is a multi-center, open-label, non-randomized study. Patients will receive ASP7487 (OSI-906) in combination with bortezomib and dexamethasone. Phase 1 involves dose escalation of the combination, whereas Phase 2 involves the expansion of ASP7487 (OSI-906) combined with bortezomib and dexamethasone at the MTD to establish the ORR. This trial will accrue patients with relapsed or relapsed/refractory MM - a disease state for which bortezomib is approved to treat by the FDA and Health Canada. T... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2018
Locations: Emory University Winship Cancer Institute, Atlanta, Georgia +5 locations
Conditions: Multiple Myeloma
Register for Updates
Otiprio Versus Ciprodex Tympanostomy Tube Outcomes
NCT03347461
Withdrawn
Otolaryngologists routinely administer ear drops at the time of tympanostomy tube placement in order to prevent tube otorrhea; however, there is a lack of consensus as to which drops are the most effective, and whether a post-operative regimen should be used. Utilizing drops postoperatively places the onus of administration on parents who may have various difficulties in delivering the drops to their child's ears. Additionally, prescribing drops postoperatively is a health care cost. The purpose... Read More
Gender:
ALL
Ages:
Between 6 months and 10 years
Trial Updated:
09/12/2018
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Otorrhea, Otitis Media With Effusion in Children
Register for Updates
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
NCT01861340
Completed
This research study is being done to see if combining the investigational chemotherapy drug, MEDI-551 with the known anti-myeloma drugs, Lenalidomide and Dexamethasone will reduce your myeloma cancer stem cells.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
09/06/2018
Locations: The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Myeloma
Register for Updates
Status Migrainosus - Differentiating Between Responders and Non-responders
NCT03066544
Unknown
The main goal of this study is to determine whether it is possible - in the setup of routine clinical care - to identify in individual patients who are clear responders to drug X, common denominators that are absent in individual patients who are non-responders to the same drug, and vice versa. All currently available knowledge about migraine pathophysiology will be utilized, using as much time as is needed to ask as many questions as are necessary, in an attempt to profile clear responders and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2018
Locations: Hartford HealthCare Headache Center, Wethersfield, Connecticut
Conditions: Migraine
Register for Updates
Ondansetron Versus Dexamethasone/Ondansetron to Treat Acute Nausea in the Emergency Department
NCT02985840
Terminated
Nausea is a common complaint in patients who present to the emergency department (ED). Although the number of conditions that can present with nausea are numerous, the mainstay of treatment has become intravenous ondansetron (Zofran), not only due to its rapid onset but also its availability. One of the major drawbacks to using this form is that it often needs to be redosed. This study aims to compare intravenous (IV) ondansetron alone versus IV ondansetron given with IV dexamethasone (Decadron)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2018
Locations: OhioHealth Doctors Hospital, Columbus, Ohio
Conditions: Nausea, Abdominal Pain
Register for Updates
Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
NCT02030483
Terminated
Our hypothesis is that treating relapsed or refractory multiple myeloma with PD 0332991 (Palbociclib) in combination with lenalidomide will result will be both effectively inducing myeloma plasma cell death as well maintaining a favorable side effect profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2018
Locations: Weill Cornell Medical College, New York, New York
Conditions: Multiple Myeloma
Register for Updates
VELCADE,Rituximab,Cyclophosphamide and Decadron
NCT00413959
Terminated
Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/20/2018
Locations: Onocology Specialists, S.C, Niles, Illinois +1 locations
Conditions: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
Register for Updates
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide
NCT01794039
Completed
This randomized phase II trial studies how well pomalidomide and dexamethasone work compared to lenalidomide and dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) or did not respond to previous treatment with lenalidomide (refractory). Pomalidomide and lenalidomide may help the immune system kill cancer cells and may also prevent the growth of new blood vessels that tumors need to grow. Drugs used in chemotherapy, such as dexameth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2018
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
NCT01706666
Completed
This randomized phase II trial studies how well giving bortezomib with or without combination chemotherapy works as consolidation therapy in patients with newly diagnosed multiple myeloma who have completed stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, dexamethasone, and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2018
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +3 locations
Conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Register for Updates
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
NCT03227432
Withdrawn
This research study is studying a combination of targeted therapies as a possible treatment for multiple myeloma (MM). The drugs involved in this study are: * Elotuzumab * Nivolumab * Pomalidomide * Dexamethasone
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2018
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Multiple Myeloma
Register for Updates
High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
NCT00002865
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-intensity, brief-duration chemotherapy in treating patients with relapsed or refractory acute lymphocytic leukemia.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/08/2018
Locations: Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina
Conditions: Leukemia
Register for Updates
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
NCT01428492
Completed
Phase Ib, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of GSK2110183 dosed in combination with bortezomib and dexamethasone in multiple myeloma (MM) subjects who have failed at least one line of systemic treatment. Part 1 will identify the maximum tolerated dose(s) (MTD) of the combination regimen. Schedule A - GSK2110183 administered once daily with bortezomib (1.3 mg/m2) and dexamethasone (20 mg) given biweekly. Part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2018
Locations: Novartis Investigative Site, Scottsdale, Arizona +12 locations
Conditions: Multiple Myeloma
Register for Updates